Bellevue Life Sciences Acquisition Corp
Research Bellevue Life Sciences Acquisition Corp (OSRH) on Bullrun: market cap USD 4.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOSRH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.11M
- Financial periodQ1 2026
- RevenueUSD 484.06K
- Net income-USD 9.55M
- Free cash flow-USD 5.44M
- Gross margin120.8%
Valuation Snapshot
latest market cap is USD 4.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.91M | -USD 27.06M | -USD 4.50M | 20.4% | -0.8 | USD 1.70M | USD 2.32M | USD 127.04M |
| FY2024 | USD 3.53M | -USD 2.41M | -USD 2.19M | 23.0% | -4.79 | USD 341.54K | USD 2.30M | -USD 8.33M |
| FY2023 | n/a | USD 403.78K | n/a | n/a | 0.05 | USD 15.42K | USD 2.02M | -USD 3.91M |
| FY2022 | n/a | -USD 35.39K | n/a | n/a | -0.01 | USD 124.50K | USD 1.14M | -USD 37.51K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.89M | n/a | n/a | n/a |
| 2024 | 2024-03-28 | n/a | 266.5 | n/a | n/a |
| 2023 | 2023-12-29 | n/a | 210.0 | n/a | n/a |
About Bellevue Life Sciences Acquisition Corp
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bellevue Life Sciences Acquisition Corp's market cap?
Bellevue Life Sciences Acquisition Corp's market capitalization is USD 4.11M.
What does Bellevue Life Sciences Acquisition Corp do?
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.